# Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

> **NCT05683964** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Prostate Cancer
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
- **DIAGNOSTIC_TEST:** Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan

## Key facts

- **NCT ID:** NCT05683964
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-19
- **Primary completion:** 2025-09-18
- **Final completion:** 2026-09-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05683964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05683964, "Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05683964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*